4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) was downgraded by research analysts at BMO Capital Markets from an “outperform” rating to a “market perform” rating in a report issued on Monday, Marketbeat.com reports. They presently have a $15.00 target price on the stock, down from their previous target price of $40.00. BMO Capital Markets’ target price points to a potential upside of 207.38% from the company’s current price.
Several other research firms have also issued reports on FDMT. Royal Bank of Canada lowered their price objective on 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating for the company in a research note on Thursday, November 14th. Chardan Capital reaffirmed a “buy” rating and set a $39.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Monday. Cantor Fitzgerald cut shares of 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, September 23rd. Finally, Bank of America reduced their price objective on shares of 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, 4D Molecular Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $38.56.
View Our Latest Analysis on 4D Molecular Therapeutics
4D Molecular Therapeutics Trading Up 2.5 %
Hedge Funds Weigh In On 4D Molecular Therapeutics
Institutional investors have recently modified their holdings of the stock. nVerses Capital LLC purchased a new stake in shares of 4D Molecular Therapeutics in the third quarter valued at approximately $40,000. Values First Advisors Inc. purchased a new stake in shares of 4D Molecular Therapeutics in the 3rd quarter worth $57,000. China Universal Asset Management Co. Ltd. grew its position in shares of 4D Molecular Therapeutics by 64.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company’s stock worth $108,000 after buying an additional 3,922 shares in the last quarter. Proficio Capital Partners LLC purchased a new position in shares of 4D Molecular Therapeutics during the third quarter valued at $108,000. Finally, Marquette Asset Management LLC bought a new stake in shares of 4D Molecular Therapeutics in the fourth quarter valued at about $116,000. 99.27% of the stock is owned by hedge funds and other institutional investors.
4D Molecular Therapeutics Company Profile
4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
Featured Stories
- Five stocks we like better than 4D Molecular Therapeutics
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- EV Stocks and How to Profit from Them
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.